Breast Cancer Liquid Biopsy Market Size, Share, Growth, and Industry Growth, By Type (Circulating Tumor Cells (CTCs), Cell-Free DNA (CfDNA), Extracellular Vesicles (EVs) and Other Circulating Biomarkers) By Application (Hospitals, Diagnostic Centers, Laboratories and Others), Regional Insights, and Forecast From 2024 To 2031

Breast Cancer Liquid Biopsy Market Report Overview

• 

•  Request a Free Sample to learn more about this report

The global breast cancer liquid biopsy market size is USD 320.8 million in 2021 and is projected to touch USD 1627.8 million by 2031, exhibiting a CAGR of 17.4% during the forecast period. 

Breast cancer liquid biopsy is a technique for collecting and analysing circulating tumour DNA (ctDNA) or other biomarkers in breast cancer patients' blood. This non-invasive technology gives vital information regarding tumour genetic mutations and changes, enabling for early detection, treatment response monitoring, and identification of potential resistance mechanisms.

Several factors, including the rising prevalence of breast cancer globally, are driving the Breast Cancer Liquid Biopsy Market. As the prevalence of breast cancer rises, there is an increasing demand for non-invasive and effective diagnostic techniques. Liquid biopsy is a promising approach since it provides real-time information regarding tumour features without intrusive procedures.

COVID-19 Impact: The COVID-19 Underlying Condition had a Gruesome Effect on the Market Growth

The global COVID-19 pandemic has been unprecedented and staggering, with the breast cancer liquid biopsy market experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden spike in CAGR is attributed to the market's growth and demand returning to pre-pandemic levels once the pandemic is over.

The pandemic of COVID-19 is predicted to have a detrimental impact on market growth. The pandemic had a number of negative consequences for breast cancer biopsy services. Because of COVID-19 lockdowns in several countries, hospitals, clinics, and diagnostic centres were unable to deliver biopsy services. The study looked at data from over 100,000 people with breast, colorectal, esophageal, or lung cancer. The study found that the pandemic will drastically affect 1- and 5-year cancer survival rates due to a lack of access to screening services. As a result, as the lockdowns continue and screening services are disrupted, cancer survivorship will decrease.

LATEST TRENDS

"The Circulating Cell-Free DNA and Advancements in Genomic Technologies to Attract the Market Share"

Circulating cell-free DNA (cfDNA) in plasma provides a non-invasive approach to real-time tumour molecular profiling at several time points, detection of developing genomic abnormalities associated with medication resistance, and clarification of cancer prognosis and diagnosis of cancer recurrence or progression. There are numerous companies that provide cfDNA-based products for research purposes. Furthermore, advances in genetic technologies and sequencing procedures have enhanced the sensitivity and specificity of liquid biopsy testing dramatically. This has made it easier to diagnose minimum residual disease, track therapy efficacy, and identify actionable mutations in breast cancer patients.

Breast Cancer Liquid Biopsy Market Segmentation

• 

•  Request a Free Sample to learn more about this report

• By Type

Based on type the breast cancer liquid biopsy market is classified into circulating tumor cells (CTCs), cell-free DNA (CfDNA), extracellular vesicles (EVs) and other circulating biomarkers.

The circulating tumor cells (CTCs) is the leading part of the type segment in the market.

• By Application

Based on application the breast cancer liquid biopsy market is classified as hospitals, diagnostic centers, laboratories and others"."

The hospital for the leading application in the market.

DRIVING FACTORS

"Convenience Over the Traditional Methods to Enhance the Market Growth"

Traditional breast cancer screening approaches, such as tissue biopsies, are insufficient to forecast or capture the complete genetic landscape of breast tumours. When compared to other genetic testing procedures, such as tumour biopsies, liquid biopsies provide distinct advantages. Blood sample collection is a less invasive approach that can provide a better knowledge of cancer. A significant advantage of breast cancer liquid biopsy is the ability to detect tumours that are smaller than those identifiable by typical imaging-based screening approaches. In reality, liquid biopsy can analyse cancer DNA rather than tumour mass, allowing for earlier tumour identification.

"Global Increase in the Breast Cancer Cases to Reinforce the Market Growth"

The global increase in breast cancer cases is one of the primary reasons driving market growth. Breast cancer is the most common type of cancer among women worldwide, according to the World Health Organisation (WHO). Breast cancer affects around 2.1 million women each year, and it is the leading cause of cancer-related deaths in women. Breast cancer was projected to have killed over 627,000 women in 2018, accounting for nearly 15% of all cancer deaths among women worldwide. According to Breast Cancer Care WA Incorporated, 19,371 Australian women were diagnosed with breast cancer in 2019, or around 53 per day, accounting for approximately 14% of all new cancer cases diagnosed.

Furthermore, breast cancer is the most frequent cancer in the United Kingdom, accounting for 15% of all new cancer cases, according to Cancer Research UK. The high prevalence of breast cancer, as well as the growing desire for better minimally invasive therapy, are the primary driving forces in the breast cancer liquid biopsy market.

RESTRAINING FACTORS

"The Costs Associated with the Tests to Hamper the Market Share"

The expense of the tests, as well as the lack of sensitivity and specificity associated with them, are important impediments to market growth. The cost of breast cancer liquid biopsy testing ranges from USD 299 and $5,000, and the tests have been shown to give false positives on occasion, increasing the danger of clinicians over-treating patients and thus impeding the breast cancer liquid biopsy market growth.

Breast Cancer Liquid Biopsy Market Regional Insights

• 

•  Request a Free Sample to learn more about this report

"North American Region to Rule Out with Advanced Diagnostic Technologies and Established Healthcare Facilities"

The North American region is likely to account for a sizable portion of the breast cancer liquid biopsy market share. This is partly due to rising breast cancer occurrences and a growing need for non-invasive therapy in this region.

 According to the National Breast Cancer Foundation of America, 62% of breast cancer diagnoses in 2019 were identified at a localized stage. In the United States, female breast cancer accounted for around 15.2% of all new cancer cases. Furthermore, the widespread adoption of modern diagnostic technologies such as PCR and NGS among healthcare professionals, as well as the presence of well-established healthcare infrastructure, are propelling the entire regional market to new heights.

KEY INDUSTRY PLAYERS

"Prominent Manufacturers to Contribute Towards Expansion of Market"

The report is an extensive research which presents the historic and futuristic performance of industry with competitive landscape analysis which incorporates prominent key players, and revenue trends of industry. The report provides substantial analysis of company profiling, growth insights, supply-demand chain, production and consumption demand, business expansion strategies adopted by top key players. The information is a collusion of latest technological developments, trends, production lines mergers and acquisitions, market study and other factors.

LIST OF TOP BREAST CANCER LIQUID BIOPSY COMPANIES

• QIAGEN (The Netherlands)
• Roche Diagnostics (India)
• Bio-Rad Laboratories (U.S.A)
• Myriad Genetics (U.S.A)
• Menarini Silicon Biosystems (France)
• Genomic Health (U.S.A)
• Thermo Fisher Scientific (U.S.A)
• Illumina (U.S.A)
• Biocept (U.S.A)
• Trovagene (U.S.A)
• Guardant Health (U.S.A)
• RainDance Technologies (Germany).

REPORT COVERAGE

The report anticipates a detailed analysis of the global market size at the regional and national level, the segmentation market growth and market share. The prime objective of the report is to help user understand the market in terms of definition, market potential, influencing trends, and the challenges faced by the market. Analysis of sales, the impact of the market players, recent developments, opportunity analysis, strategic market growth analysis, territorial market expansion, and technological innovations are the subject matter explained in the report.